Jan. 20 at 8:16 PM
$DERM (L)
Interesting move today on above avg volume (caveat, could always see "sell the news" reaction if Emrosi launch metrics for Q4 disappoint)
Has been in "Companies I'd Start With" section of our Weekly Recap since entered in October & added on dips to
$7 (to 10% portfolio weighting, maximum allowed for commercial-stage companies)
Emrosi well-positioned to become preferred treatment for inflammatory lesions of rosacea
As more confidence is built with the derm community, sales marketing organization will be asking for switches as well from Oracea over to Emrosi
They expect ratio of refills to new prescriptions will also increase, which should help accelerate prescription growth
IP to 2039= long runway for growth (key part of selection criteria)
